Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · April 09, 2022

Long-Term Persistence of First-Line Biologics for Patients With Psoriasis and Psoriatic Arthritis

JAMA Dermatology


Additional Info

JAMA Dermatology
Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database
JAMA Dermatol 2022 Mar 23;[EPub Ahead of Print], L Pina Vegas, L Penso, P Claudepierre, E Sbidian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading